[{"indications": "Indications\u00a0\n(From 8.1.3 Antimetabolites: British National Formulary)\nTioguanine is given by mouth for the treatment of acute leukaemias and chronic myeloid leukaemia. It can be given at various stages of treatment in short-term cycles. Tioguanine has a lower incidence of gastro-intestinal side-effects than mercaptopurine. Long-term therapy is no longer recommended because of the high risk of liver toxicity; treatment with tioguanine should be discontinued if liver toxicity develops.", "name": "TIOGUANINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.1 Cytotoxic drugs", "8.1.3 Antimetabolites"], "cautions": "Cautions\u00a0see section 8.1 and notes above; thiopurine methyltransferase status\r\n(see section 8.2.1); monitor liver\r\nfunction weekly\u2014discontinue if liver toxicity develops;  interactions: Appendix 1 (tioguanine)", "side-effects": "Side-effects\u00a0see section 8.1; also stomatitis and hepatotoxicity; rarely intestinal necrosis and perforation", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4740.htm", "doses": ["100\u2013200\u00a0mg/m2 daily"], "pregnancy": "Pregnancy\u00a0avoid (teratogenicity reported when men receiving tioguanine have fathered children); ensure effective contraception\r\nduring treatment in men or women; see also Pregnancy and Reproductive\r\nFunction"}]